Actively Recruiting
Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)
Led by Lund University Hospital · Updated on 2023-09-18
116
Participants Needed
1
Research Sites
329 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lung transplantation (LTx) remains the gold standard for treating patients with irreversible end-stage pulmonary disease. Of the major organs transplanted, survival in LTx recipients remains the lowest (mean 5 years). Despite improvements, primary graft dysfunction (PGD), as defined by respiratory insufficiency and edema up to 72 hours post LTx, remains the leading cause of early mortality and contributes to the development of chronic lung allograft dysfunction (CLAD) which is the leading cause of late mortality. PGD develops within the first 72 hours after LTx. The development of CLAD increases quickly with cumulative incidence of 40-80 % within the first 3-5 years. There is a general lack of efficient treatments for PGD and CLAD. Prevention of PGD is therefore of crucial importance and has a direct impact on survival. The present study is a randomized controlled study which aims to compare patients undergoing LTx with and without the utilization of cytokine adsorption.
CONDITIONS
Official Title
Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eligible to undergo double lung transplantation at either trial site
You will not qualify if you...
- Under 18 years of age
- Previous organ transplantation
- Current immunosuppressive therapy with drugs like Cyclosporine, Tacrolimus, Everolimus, or Sirolimus for at least 1 month before transplantation
- Use of any antibody-based immunomodulatory treatment up to 1 week before transplantation
- Declines to consent to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sandra Lindstedt
Lund, Skåne County, Sweden, 224 60
Actively Recruiting
Research Team
S
Sandra Lindstedt, MD,PhD
CONTACT
J
Jesper Magnusson, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here